AI and Clinical Research working together
WondermedAI connects what you prescribe, what your patient experiences, and what happens between visits into one system that personalizes care to every patient you treat.
Intelligent, personalized prescribing
and optimization of psychiatric medications
and optimization of psychiatric medications
Wonder AI Pharmacology™ uses advanced AI to support personalized psychiatric pharmacotherapy, guiding medication selection, dosing, and duration.
A safer alternative to opioids for chronic pain
- FDA 505(b)(2) Pathway
- Leading Academic Partner
- Study Launch: Q2 2027
- Target NDA: 2030
FDA 505(b)(2) Pathway · Leading Academic Partner Study Launch: Q2 2027 · Target NDA: 2030
- 12-Week Virtual Protocol combining low-dose ketamine, supplements, CBT, mindfulness, and coaching
- AI-Assisted opioid tapering with human-in-the-loop clinical oversight via WondermedAI
- Continuous monitoring with real-time safety alerts via WondermedAI
- Proprietary AI abuse surveillance designed for patient safety and regulatory compliance
- Adaptive FDA Phase 2/3 design enabling accelerated clinical development
A breakthrough protocol for chronic pain and a safe alternative to opioids.
Wonder Relief vs. Opioids:
- Efficacy – Opioids show diminishing returns and tolerance over time. Ketamine’s NMDA antagonism provides sustained analgesia in CRPS and neuropathic pain.
- Safety – Nearly 75% of U.S. overdose deaths in 2020 involved opioids. Wonder Relief integrates AI misuse detection, clinician oversight, and harm-reduction safeguards.
- Durability – Opioids mask symptoms without retraining pain circuits. Wonder Relief promotes neuroplasticity through ketamine, CBT, and MBSR to recondition maladaptive networks.
- Accessibility & Cost – Chronic opioid therapy drives high costs and ER utilization. Wonder Relief is telemedicine-based, with integrated coaching and peer support for scalable access.
AI-guided protocol for anxiety and depression
FDA 505(b)(2) Pathway · Leading Academic Partner Study Launch: Q4 2027 · Target NDA: 2031
- Flow State Protocol – Built on the neuroscience of flow to enhance neuroplasticity and therapeutic outcomes
- Wonder Ketamine Lozenges – Proprietary formulation paired with cannabinoids to optimize efficacy and tolerability
- WonderFlow Daily Supplement – Designed to support neuroplasticity, recovery, and treatment continuity
- AI Personalization – Adaptive dosing, timing, and intervention pathways powered by patient response
- Validated V1 Learnings – Refined from 1,500+ patients and IRB-backed clinical data
The
protocol
Components:
- Daily practices designed to guide the mind into sustained flow state for healing.
- Daily Organic Supplementation: Functional mushrooms and botanicals designed to support neuroplasticity and balance.
- Wonder Ketamine Lozenges (100–400 mg): Administered 4–8x monthly, acting as a neuromodulatory primer for flow-state induction.
- Clinical Integration: Licensed clinicians and coaches provide monitoring, outcome tracking (PHQ-9, GAD-7), and safety protocols.
WonderFlow is a validated psychedelic protocol delivering measurable outcomes and a more accessible alternative to Spravato.
Turn your practice into a center of
mental healthcare excellence
mental healthcare excellence